中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 北京市竞天公诚律师事务所 关于北京莱伯泰科仪器股份有限公司 2023 年第二次临时股东大会的法律意见书 本所在此同意，公司可以将本法律意见书作为本次股东大会公告的法定文件， 随其他公告文件一并提交上海证券交易所予以审核公告。 本所律师根据《股东大会规则》第五条的要求，按照律师行业公认的业务标 准、道德规范和勤勉尽责精神，对本次股东大会的召集和召开的有关事实及公司 1 提供的文件进行了核查和验证，并对本次股东大会进行现场见证，现出具法律意 见如下： 一、本次股东大会的召集、召开程序 1、本次股东大会的召集程序 本次股东大会由公司董事会根据2023年10月27日召开的公司第四届董事会 第九次会议决议召集。经本所律师查验，公司董事会于2023年10月28日在上海证 券交易所网站（www.sse.com.cn）及《上海证券报》《中国证券报》上刊登了《北 京莱伯泰科仪器股份有限公司关于召开2023年第二次临时股东大会的通知》（以 下简称"《通知 ...

证券代码：688056 证券简称：莱伯泰科 公告编号：2023-041 北京莱伯泰科仪器股份有限公司 2023 年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2023 年 11 月 14 日 （二） 股东大会召开的地点：北京市顺义区空港工业区 B 区安庆大街 6 号北京 莱伯泰科仪器股份有限公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 14 | | --- | --- | | 普通股股东人数 | 14 | | 2、出席会议的股东所持有的表决权数量 | 43,910,266 | | 普通股股东所持有表决权数量 | 43,910,266 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 65.3072 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例 ...

证券代码：688056 证券简称：莱伯泰科 北京莱伯泰科仪器股份有限公司 投资者关系活动记录表 编号：2023-014 投资者关系 □特定对象调研 □分析师会议 活动类别 □媒体采访 业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名 2023年 11月8日下午 称 广大投资者 会议时间及 2023年 11月8日下午 会议方式 通过上证路演中心网络互动的方式 上市公司接 董事长兼总经理，胡克 待人员姓名 董事、董事会秘书兼财务总监，于浩 独立董事，孔晓燕 董事长胡克博士做开场致辞并欢迎广大投资者参加公司 2023 年第三 季度业绩说明会；董事长胡克博士和董事会秘书于浩女士通过网络互动的 方式回复了广大投资者提出的问题。 ...

证券代码：688056 证券简称：莱伯泰科 北京莱伯泰科仪器股份有限公司 投资者关系活动记录表 编号：2023-014 | 投资者关系 | □特定对象调研 □分析师会议 | | --- | --- | | 活动类别 | □媒体采访 业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名 | 2023 年 11 月 8 日下午 | | 称 | 广大投资者 | | 会议时间及 | 2023 年 11 月 8 日下午 | | 会议方式 | 通过上证路演中心网络互动的方式 | | 上市公司接 | 董事长兼总经理，胡克 | | 待人员姓名 | 董事、董事会秘书兼财务总监，于浩 | | | 独立董事，孔晓燕 | | | 董事长胡克博士做开场致辞并欢迎广大投资者参加公司 2023 年第三 | | | 季度业绩说明会；董事长胡克博士和董事会秘书于浩女士通过网络互动的 | | | 方式回复了广大投资者提出的问题。 | | 投资者关系 | 网络互动环节 | | 活动主要内 | 问题 1：请问胡总，公司新增多项研发项目，是否都是公司产品线需要的 ...

证券代码：688056 证券简称：莱伯泰科 北京莱伯泰科仪器股份有限公司 2023 年第二次临时股东大会 会议资料 2023 年 11 月 北京莱伯泰科仪器股份有限公司 2023年第二次临时股东大会会议资料 2023 年第二次临时股东大会会议资料 出席会议的股东及股东代理人须在会议召开前 30 分钟到会议现场办理签到 手续，并请按规定出示证券账户卡（如有）、身份证明文件或法人单位证明、授 权委托书等，经验证后方可出席会议。 二、为保证本次大会的严肃性和正常秩序，切实维护与会股东（或股东代理 人）的合法权益，务请出席大会的股东或其代理人或其他出席者准时到达会场签 到确认参会资格。会议开始后，会议登记终止。 三、会议按照会议通知上所列顺序审议、表决议案。 目录 | 年第二次临时股东大会会议须知 2023 2 | | --- | | 2023 年第二次临时股东大会会议议程 4 | | 议案一：关于首次公开发行股票部分募集资金投资项目结项并将节余募集资金 | | 用于新建项目及永久补充流动资金的议案 6 | | 议案二：关于使用部分募集资金投资项目节余资金新建项目的议案 11 | | 议案三：关于修订《公司章程》并办 ...

Group 1: Company Overview - Beijing Leibotai Technology Co., Ltd. is actively expanding its R&D personnel to support new product development, particularly by recruiting high-end talent [2] - The company is currently focusing on the orderly advancement of all new projects [2] Group 2: Key Personnel - Dr. Cui Jianfeng has been appointed as the Deputy General Manager of the Mass Spectrometry Division, responsible for product development and management [3] - Dr. Cui has extensive experience in the lifecycle of mass spectrometry products, having previously worked at Thermo Fisher [3] Group 3: Customer Base Changes - The customer base remains primarily composed of government departments, research institutions, universities, third-party testing firms, and corporate clients [3] - There has been a slight decrease in revenue from government departments, while the share from corporate clients, research institutions, and universities has increased compared to the previous year [3] Group 4: R&D Expenditure - The increase in R&D expenses in Q3 2023 is attributed to new key projects and the hiring of high-end R&D personnel, leading to higher salary costs [3] - Additional costs include materials and depreciation of R&D instruments [3] Group 5: Product Validation - The company does not require extensive product validation for new semiconductor clients, as the ICP-MS product has been positioned as a premium offering since its launch in May 2021 [3] Group 6: Collaborations - The company has signed two significant procurement contracts with the China National Institute of Metrology, focusing on automated radiochemical analysis systems and plasma mass spectrometry [3]

证券代码：688056 证券简称：莱伯泰科 公告编号：2023-040 北京莱伯泰科仪器股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 11 月 08 日(星期三)下午 14:00-15:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 11 月 01 日(星期三)至 11 月 07 日(星期二)16:00 前登录上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 zqtzb@labtechgroup.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 北京莱伯泰科仪器股份有限公司（以下简称"公司"）已于 2023 年 10 月 28 日发布公司 2023 年第三季度报告 ...

[Key Financial Data](index=1&type=section&id=Item%20I.%20Key%20Financial%20Data) [Key Accounting Data and Financial Indicators](index=1&type=section&id=Item%20I.%28I%29%20Key%20Accounting%20Data%20and%20Financial%20Indicators) In Q3 2023, the company's operating revenue increased year-over-year, but net profit attributable to shareholders and non-recurring net profit both declined significantly by approximately 70% 2023 Q3 and YTD Core Financial Indicators | Indicator | Current Period (Q3 2023) | YoY Change (Current Period) | Year-to-Date (YTD Q3 2023) | YoY Change (YTD) | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue (RMB) | 104,000,000 | +10.88% | 300,000,000 | +20.45% | | Net Profit Attributable to Shareholders (RMB) | 3,832,400 | -69.16% | 26,660,700 | -22.77% | | Net Profit Attributable to Shareholders (Excluding Non-Recurring Items) (RMB) | 3,524,100 | -70.76% | 24,870,200 | -23.46% | | Basic Earnings Per Share (RMB/share) | 0.06 | -66.67% | 0.40 | -21.57% | | Total R&D Investment (RMB) | 15,139,200 | +53.22% | 36,857,400 | +36.71% | - As of the end of the reporting period, the company's total assets were **993 million RMB**, a **3.24% increase** from the end of the previous year; owner's equity attributable to listed company shareholders was **849 million RMB**, a **2.71% increase** from the end of the previous year[6](index=6&type=chunk) [Non-Recurring Gains and Losses Items and Amounts](index=2&type=section&id=Item%20I.%28II%29%20Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) Year-to-date, the company's non-recurring gains and losses totaled **1.7905 million RMB**, primarily from government grants and investment income Year-to-Date Main Non-Recurring Gains and Losses Items | Item | Amount (RMB) | | :--- | :--- | | Government grants included in current profit and loss | 815,099.28 | | Fair value changes and investment income from transactional financial assets, etc. | 1,347,589.19 | | Income tax impact | -357,419.97 | | **Total** | **1,790,490.19** | - The company classified **1.7161 million RMB** in software tax refunds as recurring gains and losses, as it is directly related to and frequently occurs in daily sales operations[11](index=11&type=chunk) [Analysis of Changes in Key Accounting Data and Financial Indicators](index=4&type=section&id=Item%20I.%28III%29%20Analysis%20of%20Changes%20in%20Key%20Accounting%20Data%20and%20Financial%20Indicators) The company explained the significant fluctuations in key financial indicators for the current reporting period, attributing net profit decline to market and cost factors, while improved operating cash flow resulted from increased collections and reduced procurement - Q3 net profit significantly declined (**-69.16%**) primarily due to: - Market demand falling short of expectations and increased competition leading to lower gross profit margins[11](index=11&type=chunk) - Increased depreciation and property-related expenses after the new production base was put into operation[11](index=11&type=chunk) - Increased investment in R&D personnel and materials due to new key R&D projects[11](index=11&type=chunk) - Increased market promotion and marketing expenses for new products[11](index=11&type=chunk) - Net cash flow from operating activities turned positive year-to-date, mainly due to a **20.45% increase** in revenue, a corresponding increase in cash received from sales, and sufficient prior inventory reserves leading to a lower increase in current period procurement expenditures compared to revenue growth[11](index=11&type=chunk) - R&D investment for the current period and year-to-date significantly increased (**53.22%** and **36.71%** respectively), primarily due to the company's new key R&D projects, recruitment of high-end R&D personnel leading to increased compensation expenses, and increased R&D material investment and instrument depreciation costs[12](index=12&type=chunk) [Shareholder Information](index=5&type=section&id=Item%20II.%20Shareholder%20Information) [Total Number of Common Shareholders, Number of Preferred Shareholders with Restored Voting Rights, and Top Ten Shareholders' Shareholding Status](index=5&type=section&id=Item%20II.%28I%29%20Total%20Number%20of%20Common%20Shareholders%2C%20Number%20of%20Preferred%20Shareholders%20with%20Restored%20Voting%20Rights%2C%20and%20Top%20Ten%20Shareholders%27%20Shareholding%20Status) As of the end of the reporting period, the company had **3,961** common shareholders, with the top two shareholders, Beijing LabTech Management Consulting Co., Ltd. and LabTech Holdings, Inc., holding nearly **60%** of shares, both controlled by the actual controller, Mr. Hu Ke Top Ten Shareholders' Shareholding Status | Shareholder Name | Nature | Shareholding Ratio (%) | Number of Shares | | :--- | :--- | :--- | :--- | | Beijing LabTech Management Consulting Co., Ltd. | Domestic Non-State Legal Person | 35.96 | 24,177,000 | | LabTech Holdings, Inc. | Overseas Legal Person | 23.97 | 16,118,000 | | Yu Hao | Domestic Natural Person | 2.13 | 1,432,446 | | Wang Yi | Domestic Natural Person | 1.80 | 1,210,084 | | Zhou Yixia | Domestic Natural Person | 1.47 | 985,718 | - As of the end of the reporting period, the company had a total of **3,961** common shareholders[14](index=14&type=chunk) - Major shareholder related party relationship: Beijing LabTech Management Consulting Co., Ltd. and LabTech Holdings, Inc. are both controlled by the company's actual controller, Hu Ke, forming a concerted action party[15](index=15&type=chunk) [Quarterly Financial Statements](index=7&type=section&id=Item%20IV.%20Quarterly%20Financial%20Statements) [Consolidated Balance Sheet](index=7&type=section&id=Consolidated%20Balance%20Sheet) As of September 30, 2023, the company's total assets were **993 million RMB**, a **3.24% increase** from the end of the previous year, with total liabilities at **144 million RMB**, and owner's equity attributable to the parent company at **849 million RMB** Balance Sheet Key Items (Unit: RMB) | Item | September 30, 2023 | December 31, 2022 | Change Rate | | :--- | :--- | :--- | :--- | | Cash and Bank Balances | 360,902,020.11 | 372,840,403.11 | -3.20% | | Inventories | 177,715,677.03 | 156,211,160.24 | +13.77% | | Fixed Assets | 148,536,316.13 | 138,552,579.34 | +7.21% | | **Total Assets** | **992,682,606.38** | **961,529,356.81** | **+3.24%** | | Contract Liabilities | 64,738,519.85 | 56,884,725.70 | +13.81% | | **Total Liabilities** | **143,634,816.05** | **134,852,233.51** | **+6.51%** | | **Owner's Equity Attributable to Parent Company** | **849,047,790.33** | **826,677,123.30** | **+2.71%** | [Consolidated Income Statement](index=9&type=section&id=Consolidated%20Income%20Statement) In the first three quarters of 2023, the company achieved operating revenue of **300 million RMB**, a **20.45% year-over-year increase**, but net profit attributable to parent company shareholders declined by **22.77%** due to faster growth in costs and expenses 2023 YTD Income Statement Key Items (Unit: RMB) | Item | 2023 YTD | 2022 YTD | YoY Change | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 299,949,773.52 | 249,029,652.65 | +20.45% | | Operating Cost | 166,250,340.66 | 127,128,861.33 | +30.77% | | Selling Expenses | 52,695,236.03 | 41,943,636.29 | +25.63% | | Administrative Expenses | 22,206,457.37 | 18,325,867.20 | +21.18% | | R&D Expenses | 36,857,433.66 | 26,960,651.01 | +36.71% | | Operating Profit | 26,393,003.74 | 38,845,360.09 | -32.06% | | Net Profit Attributable to Parent Company | 26,660,681.40 | 34,522,516.63 | -22.77% | | Basic Earnings Per Share | 0.40 | 0.51 | -21.57% | [Consolidated Cash Flow Statement](index=12&type=section&id=Consolidated%20Cash%20Flow%20Statement) In the first three quarters of 2023, net cash flow from operating activities significantly improved to **15.77 million RMB** from a net outflow in the prior year, primarily driven by increased cash received from sales 2023 YTD Cash Flow Statement Key Items (Unit: RMB) | Item | 2023 YTD | 2022 YTD | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 15,767,147.36 | -15,285,465.54 | | Net Cash Flow from Investing Activities | -17,548,539.70 | -122,127,608.34 | | Net Cash Flow from Financing Activities | -12,806,073.96 | -19,766,642.13 | | Net Increase in Cash and Cash Equivalents | -11,302,599.11 | -146,374,428.20 | | Cash and Cash Equivalents at End of Period | 360,201,276.47 | 348,171,551.13 | - The improvement in operating cash flow is mainly due to cash received from sales of goods and services increasing from **273 million RMB** to **332 million RMB**, a **21.6% year-over-year increase**[26](index=26&type=chunk)

一、预留限制性股票的分配情况 | 序号 姓名 | 国籍 | 职务 | 获授限制性 股票数量 | 占授予限 制性股票 | 占本激励 计划公告 | | --- | --- | --- | --- | --- | --- | | | | | （万股） | 总数比例 | 日股本总 | | | | | | | 额比例 | | 一、董事、高级管理人员、核心技术人员 | | | | | | | / | / | / | / | / | / | | 二、核心业务骨干人员（共 4 人） | | | 5.00 | 4.71% | 0.07% | | 三、预留剩余 | | | 16.00 | 15.08% | 0.24% | | 合计 | | | 21.00 | 19.79% | 0.31% | 注：1、上述任何一名激励对象通过全部在有效期内的股权激励计划获授的本公司股票均未超过公司总 股本的 1%。公司全部有效的激励计划所涉及的标的股票总数累计不超过股权激励计划提交股东大会时公 司股本总额的 20%。 2、本计划的激励对象不包括独立董事、监事、单独或合计持有上市公司 5%以上股份的股东、上市 公司实际控制人及其配偶、父母、子女以及 ...

北京莱伯泰科仪器股份有限公司 董事会议事规则 北京莱伯泰科仪器股份有限公司 董事会议事规则 第一章 总则 第一条 为了进一步规范北京莱伯泰科仪器股份有限公司（以下简称"公司"或 "本公司"或"上市公司"）董事会的议事方式和决策程序，促使董事和董事会 有效地履行其职责，提高董事会规范运作和科学决策水平，根据《中华人民共 和国公司法》、《中华人民共和国证券法》、《上海证券交易所科创板股票上市规 则》、《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等 法律、行政法规和规范性文件以及《北京莱伯泰科仪器股份有限公司章程》（以 下简称"《公司章程》"）的规定，制订本规则。 第二条 董事会下设董事会办公室，处理董事会日常事务。 第三条 董事会秘书担任董事会办公室负责人，对上市公司和董事会负责， 保管董事会和董事会办公室印章，负责信息披露事务。 第二章 董事会的组成和职权 第四条 董事会由 7 名董事组成，其中独立董事 3 名。 第五条 董事会行使下列职权： （九）拟订公司重大收购、收购本公司股票或者合并、分立、解散及变更 1 （一）召集股东大会，并向股东大会报告工作； （二）执行股东大会的决议； （三） ...